World
GSK shares dive as weaker vaccine sales unnerve investors
British pharma company one of biggest fallers on FTSE 100 despite better than expected financial results Business live – latest updates Shares in GSK slid on Wednesday despite the UK drugmaker reporting better than expected financial results, as investors were unnerved by weaker sales of its respiratory syncytial virus (RSV) and shingles vaccines and recently launched medications. Britain’s second-biggest pharmaceutical company reported a 19% decline in pre-tax profit to £1.9bn in the July to Se
Publication and source
PublicationSanalda Haber
SourceThe Guardian
Published
CategoryWorld
Summary from the source publisher’s news feed.